New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies
Portfolio Pulse from Jelena Martinovic
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has completed its acquisition of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) for $60 million. The deal includes potential additional payments of up to $140 million subject to the achievement of specific milestones. Zynerba is known for its pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. Its lead candidate, Zygel, could serve 80,000 U.S. patients diagnosed with Fragile X syndrome and another 80,000 diagnosed with 22q deletion syndrome.
October 11, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences has completed its acquisition of Zynerba Pharmaceuticals, potentially expanding its portfolio and market reach.
The acquisition of Zynerba Pharmaceuticals allows Harmony Biosciences to expand its portfolio with a product that could serve a significant number of patients. This could potentially increase the company's market reach and revenue in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Zynerba Pharmaceuticals has been acquired by Harmony Biosciences. The company's lead candidate, Zygel, could serve a significant number of patients.
The acquisition by Harmony Biosciences could provide Zynerba Pharmaceuticals with the resources and support to further develop and market its lead candidate, Zygel. This could potentially increase the company's market reach and revenue in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100